
Peptides have the potential to expand the space of “druggable” targets. No wonder the number of them being under investigation in clinical trials or used as therapeutics is growing. This is accompanied by an increasing need to produce them efficiently and cost-effectively. However, large-scale manufacturing of these active pharmaceutical ingredients (APIs) involves many challenges from decreasing yields when synthesizing molecules with more building blocks to the enormous amounts of solvents needed for synthesis and purification. The only way to make the chemical production of these APIs more efficient and sustainable is to bring new solutions for all steps of the manufacturing processes. This can be achieved either through process optimizations or by using new innovative technologies.
There are a variety of ideas and solutions to tackle these challenges. We would like to share a few examples where we have first-hand experience:
Implementation of a new level of automation and digitalization of solid-phase peptide synthesis (SPPS) to meet the predicted rise in demand for capacity and compliance.

Produce shorter peptides without hazardous solvents, with more efficient scale-up and enhanced process controls using TAPS.
Fewer washing and filtration steps are needed compared to classic peptide synthesis, resulting in a reduction of up to 60% in the use of organic solvents.

Using CEPS for the production of larger peptides with more than 40 amino acids or even the production of small proteins. Peptiligase enzymes offer a scalable alternative for large-scale manufacturing and enable a more economical manufacturing not only of large linear peptides but also of cyclic peptide drugs and (bio)conjugates. We are investigating this together with our partner EnzyTag.
Purification can be a bottleneck in the production of peptides and oligonucleotides because of the enormous amounts of solvents involved. We addressed this challenge with incorporation of MCSGP into the downstream process and set up the first continuous chromatography system for center cut purification of peptides and oligonucleotides at industrial scale. Compared to single-column batch purification, solvent consumption is typically decreased by over 30%, thus contributing to a higher level of sustainability. The process has a higher capacity and often reaches the target product purity often with a higher yield, typically 10% more.

The last three innovations (TAPS, CEPS and MCSGP) mentioned are examples of our green chemistry success stories.
Find more detailed information on these innovations and others,
in our innovation brochure:
Stay tuned, there is more to come, since our technological leadership and innovative strength have been the cornerstones of our success since the very beginning of our company more than 50 years ago. It might be that your project can benefit from the innovative processes we are developing with our partners. Contact us to see how we can help you! Or, for more information on the process of manufacturing peptides, have a read of our our peptide manufacturing guide, covering all the key aspects.
Looking for a convenient tool to determine peptide molecular weight? Try our helpful peptide calculator today.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.